Aster DM Healthcare Q4 FY26 Earnings Preview & Outlook
Aster DM Healthcare latest news:
Updated: 25 Mar 2026 • 4:11 pm
Posted by:
Aster DM Healthcare Q4 Results 2026 Preview
- Aster DM Healthcare Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 13-18% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 15-22% YoY.
- EBITDA to rise 17%.
- Aster DM Healthcare is expected to show Strong Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Aster DM Healthcare Share Performance
- Over the past six months, Aster DM Healthcare share price has Up by 18-25% to 646.35.
- Moreover, over the past year, the stock has Up by 34%
- Despite this weak short-term performance, Aster DM Healthcare stock has delivered a financially sound 230% return over the past 5 years.
- As of today, 25-03-2026, the Aster DM Healthcare share price is trading at 646.35 per share.
Key Factors to Watch for Aster DM Healthcare Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Hospital Chain industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
Visit Univest app or website to check more Aster DM Healthcare latest news to make an informed investment decision.
About Aster DM Healthcare
Aster DM Healthcare operates hospitals, clinics, and pharmacies across India and the Middle East. The company focuses on affordable healthcare, expansion of medical infrastructure, and improving patient services.
Visit Univest app or website to check more Aster DM Healthcare latest news to make an informed investment decision.
Final Thoughts
Aster DM Healthcare is gear up to announce its Q4 FY26 results. Analysts expect 13-18% revenue growth, a 15-22% rise in PAT, and a 17% rise in EBITDA. Aster DM Healthcare focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Aster DM Healthcare Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Arkade Developers Q4 Results 2026 Preview & Earnings
Arisinfra Solutions Q4 Results 2026 Preview & Earnings
Archidply Industries Q4 results preview with revenue outlook and earnings estimates.
Aqylon Nexus Q4 Results 2026 Preview & Earnings
Apollo Pipes Q4 Results 2026 Preview, Earnings & Demand Outlook
Recent Articles
Tata Consumer Products Shares Jump 7% After Q2 Results: Is This Tata Group Stock a Buy Now? Elara Target, Price Hikes, Valuation and Risks
27 October 2026
Acutaas Chemicals Shares Jump 13% to a Record High After Q2 Profit Rises 71%, Up About 580% in 5 Years: Guidance, Valuation and Risks
27 October 2026
Amazon Stock: Morgan Stanley and UBS Raise Price Targets Ahead of Q3 Results on 29 October, but What Do AWS Margins, Capex and Risks Say?
27 October 2026
Nifty FMCG Index Is Down 22% in 2026: Is Diwali a Buying Opportunity? Valuation, Margin Pressure, Technical Levels and Stocks to Watch
27 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Tata Consumer Products Shares Jump 7% After Q2 Results: Is This Tata Group Stock a Buy Now? Elara Target, Price Hikes, Valuation and Risks
Acutaas Chemicals Shares Jump 13% to a Record High After Q2 Profit Rises 71%, Up About 580% in 5 Years: Guidance, Valuation and Risks
Amazon Stock: Morgan Stanley and UBS Raise Price Targets Ahead of Q3 Results on 29 October, but What Do AWS Margins, Capex and Risks Say?
Nifty FMCG Index Is Down 22% in 2026: Is Diwali a Buying Opportunity? Valuation, Margin Pressure, Technical Levels and Stocks to Watch
Fujiyama Power Systems Shares: Motilal Oswal Sees 36% More Upside With a Rs 500 Target, but Is This Rooftop Solar Stock Still a Buy? Q1 Numbers, Valuation and Risks
Popular this week
Jio Financial Services Share Price Decoded: Reliance Stock Performance Amid Jio Platforms Listing Buzz, Q2 Results, Outlook and Key Levels
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times